Investigators used next-generation sequencing to characterize the genomic profile of squamous cell carcinoma (SCC) in 26 Colombian patients with lung SCC.
Investigators analyzed the effect of EGFR inhibition on VEGF and HIF-1α in non-small cell lung cancer models.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.
In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.
The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.
Investigators assessed the impact of immune checkpoint inhibition in patients with non–small lung cancer and MET-amplified or MET exon 14-mutant tumors.
The approval was based on data from the double-blind, placebo-controlled phase 3 ADAURA study.
PD-1/PD-L1 inhibitors offer an improvement over standard of care in SCLC, but there is still a long way to go.
Pleurectomy decortication is a lung-sparing surgery that involves removal of the parietal and visceral pleura and visible tumor masses.
For patients with advanced EGFR- and ALK-positive NSCLC, higher out-of-pocket costs for tyrosine kinase inhibitors was linked to worse overall survival.
The study results can inform decision making during the COVID-19 and future pandemics.
Prognostic biomarker could be useful for perioperative decision making.
As this research finds that many patients are distressed enough to require some form of intervention, a number of stress-reduction techniques are provided that can be easily put into practice.
About one-third of patients refractory to alectinib responded.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Therapy-related AML after lung cancer is rare, but is associated with poor prognosis.
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
A DLL3-targeted BiTE demonstrated antitumor activity — but high rates of CRS — among patients with previously-treated SCLC.
Extracellular vesicles carrying PD-L1 as cargo may function as a predictive biomarker for immunotherapy response in NSCLC.